Invitation to Capital Markets Day

Recipharm has the pleasure of inviting investors, financial analysts and media to attend our Capital Markets Day on Wednesday August 31, 2016 at IVA Conference center, Grev Turegatan 16, Stockholm.

The purpose of the Capital Markets Day is to provide an update on Group performance, plan and strategy. Presentations will be held by Thomas Eldered, CEO; Björn Westberg, CFO and other members of the Group Management Team.

The program will start with registration and coffee at 09:45 and end by around 15:00.

Please register at https://www.recipharm.com/capital-markets-day-31-august-2016  before August 15. Additional details will be posted on the website later on.

For further information please visit www.recipharm.com or contact:

Björn Westberg, CFO, ir@recipharm.com, +46 8 602 46 20

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.  

For more information on Recipharm and our services, please visit www.recipharm.com  

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden,  Telephone 46 8 602 52 00,  Fax  46 8 81 87 03

www.recipharm.com

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links